877 related articles for article (PubMed ID: 25060145)
1. Plasma natriuretic peptides and incidence of subtypes of ischemic stroke.
Berntsson J; Zia E; Borné Y; Melander O; Hedblad B; Engström G
Cerebrovasc Dis; 2014; 37(6):444-50. PubMed ID: 25060145
[TBL] [Abstract][Full Text] [Related]
2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
4. Pro-atrial natriuretic peptide and prediction of atrial fibrillation and stroke: The Malmö Preventive Project.
Berntsson J; Smith JG; Nilsson PM; Hedblad B; Melander O; Engström G
Eur J Prev Cardiol; 2017 May; 24(8):788-795. PubMed ID: 28195503
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
[TBL] [Abstract][Full Text] [Related]
6. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort.
Cushman M; Judd SE; Howard VJ; Kissela B; Gutiérrez OM; Jenny NS; Ahmed A; Thacker EL; Zakai NA
Stroke; 2014 Jun; 45(6):1646-50. PubMed ID: 24757103
[TBL] [Abstract][Full Text] [Related]
7. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
[TBL] [Abstract][Full Text] [Related]
8. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
[TBL] [Abstract][Full Text] [Related]
10. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.
Dixen U; Ravn L; Soeby-Rasmussen C; Paulsen AW; Parner J; Frandsen E; Jensen GB
Cardiology; 2007; 108(1):35-9. PubMed ID: 16968988
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.
Tuñón J; Blanco-Colio L; Cristóbal C; Tarín N; Higueras J; Huelmos A; Alonso J; Egido J; Asensio D; Lorenzo Ó; Mahíllo-Fernández I; Rodríguez-Artalejo F; Farré J; Martín-Ventura JL; López-Bescós L
Am J Cardiol; 2014 Feb; 113(3):434-40. PubMed ID: 24295549
[TBL] [Abstract][Full Text] [Related]
12. Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial).
Darkner S; Goetze JP; Chen X; Henningsen K; Pehrson S; Svendsen JH
Am J Cardiol; 2017 Oct; 120(8):1309-1315. PubMed ID: 28865890
[TBL] [Abstract][Full Text] [Related]
13. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation.
Smith JG; Newton-Cheh C; Almgren P; Struck J; Morgenthaler NG; Bergmann A; Platonov PG; Hedblad B; Engström G; Wang TJ; Melander O
J Am Coll Cardiol; 2010 Nov; 56(21):1712-9. PubMed ID: 21070922
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of midregional pro-A-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years.
Karakas M; Jaensch A; Breitling LP; Brenner H; Koenig W; Rothenbacher D
Clin Chem; 2014 Nov; 60(11):1441-9. PubMed ID: 25139456
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
[TBL] [Abstract][Full Text] [Related]
16. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of N-terminal pro-brain natriuretic peptide in differentiating cardioembolic ischemic stroke.
Hajsadeghi S; Kashani Amin L; Bakhshandeh H; Rohani M; Azizian AR; Jafarian Kerman SR
J Stroke Cerebrovasc Dis; 2013 May; 22(4):554-60. PubMed ID: 23422348
[TBL] [Abstract][Full Text] [Related]
18. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
[TBL] [Abstract][Full Text] [Related]
19. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure.
Tan ESJ; Chan SP; Liew OW; Chong JPC; Gerard Leong KT; Daniel Yeo PS; Ong HY; Jaufeerally F; Sim D; Ling LH; Lam CSP; Richards AM
JACC Heart Fail; 2024 Mar; 12(3):461-474. PubMed ID: 37897459
[TBL] [Abstract][Full Text] [Related]
20. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
